Sleep · Research · 5 min read
Magnesium bisglycinate and poor sleep: a small edge over placebo
In a four-week randomized, placebo-controlled trial of 155 adults reporting poor sleep, Insomnia Severity Index (ISI) scores fell slightly more with magnesium bisglycinate than with placebo (p = 0.049). Other outcomes showed no significant difference.
Earlier magnesium and sleep trials were small and their results were mixed: a systematic review cited by the authors found two trials with improvements and three with no significant effects, 247 participants in total. A 2025 randomized, placebo-controlled trial from Germany tested one form, magnesium bisglycinate, in adults who described themselves as healthy but reported poor sleep. After four weeks, scores on the Insomnia Severity Index (ISI), a seven-item questionnaire about insomnia symptoms, fell more with magnesium bisglycinate than with placebo. The gap was small (Cohen’s d = 0.2) and only just statistically significant (p = 0.049). The placebo group improved too, and none of the other questionnaires showed a significant difference between groups. Every outcome was self-reported, and each dose also contained glycine. [1]
What the researchers did
This was a two-arm, parallel-group, four-week, double-blind, placebo-controlled trial run online and at home across Germany (trial registration DRKS00031494). Adults aged 18 to 65 who said they were in good health could join if they had slept poorly for more than four weeks, measured as a Regensburg Insomnia Scale (RIS) score above 12. People with a known sleep disorder needing care, such as sleep apnea, rotating-shift workers and people regularly taking medications affecting sleep or mood were excluded. [1]
155 people were randomized: 77 to magnesium bisglycinate and 78 to placebo. 153 were included in the intention-to-treat (ITT) analysis, and 134 completed the study. Their mean age was 41.5 years, and 122 of the 153 (79.7%) were women. [1]
- Magnesium bisglycinate: two capsules daily, 30 to 60 minutes before bedtime, giving 250 mg of elemental magnesium and 1523 mg of glycine per day.
- Placebo: visually identical capsules containing cellulose.
- Primary outcome: change in ISI score from baseline to week 4.
- Secondary outcomes: RIS, sleep quality (Single-Item Sleep Quality Scale, SQS), daytime sleepiness (Epworth Sleepiness Scale, ESS), fatigue (Fatigue Severity Scale, FSS), stress (Perceived Stress Scale, PSS), mood (Positive and Negative Affect Schedule, PANAS) and symptoms of depression and anxiety (Patient Health Questionnaire-4, PHQ-4).
Participants kept their usual diet and habits. The results below come from generalized linear mixed models (GLMM) adjusted for baseline score, age, sex, body mass index and occupation. [1]
Key findings
| Outcome | Placebo (n = 76) | Magnesium bisglycinate (n = 77) | Difference | p |
|---|---|---|---|---|
| ISI | −2.3 (−4.1 to −0.4) | −3.9 (−5.8 to −2.0) | 1.6 (0.0 to 3.3) | 0.049* |
| RIS | −1.1 (−2.7 to 0.5) | −2.0 (−3.7 to −0.4) | 1.0 (−0.5 to 2.4) | 0.186 |
| SQS | 0.3 (−0.5 to 1.2) | 1.0 (0.2 to 1.9) | −0.7 (−1.4 to 0.1) | 0.069 |
| ESS | −1.8 (−3.0 to −0.6) | −2.0 (−3.2 to −0.8) | 0.3 (−0.8 to 1.3) | 0.624 |
| FSS | −1.8 (−5.0 to 1.5) | −3.0 (−6.3 to 0.3) | 1.3 (−1.6 to 4.2) | 0.391 |
| PSS | −2.0 (−4.3 to 0.3) | −2.4 (−4.8 to −0.1) | 0.4 (−1.7 to 2.5) | 0.708 |
Insomnia scores fell more with magnesium bisglycinate, by a small margin. Adjusted ISI scores dropped 3.9 points with magnesium bisglycinate and 2.3 points with placebo. The 1.6-point difference had a 95% confidence interval of 0.0 to 3.3 and p = 0.049, and the effect size was small (Cohen’s d = 0.2). A per-protocol analysis of the 134 participants who followed the protocol pointed the same way (−5.0 vs −3.1 points, p = 0.035). [1]
The placebo group improved too. From baseline to day 28, ISI scores fell 28% in the magnesium bisglycinate group and 18% in the placebo group. [1]
“These within-group reductions suggest that both groups experienced improvements in self-reported insomnia severity, but the magnesium bisglycinate group demonstrated a significantly greater benefit over time.”
Schuster et al. · Results · full text
Fewer than a third of participants reached the paper’s bar for a clinically meaningful change. The authors counted a drop of 6 or more ISI points as a clinically significant improvement. 41 participants (30%) reached it; the paper reports 26 (19%) in the magnesium bisglycinate group and 15 (11%) in the placebo group. The authors also note that the magnesium bisglycinate group’s mean ISI score at week 4 was still in the subthreshold insomnia range. [1]
The other questionnaires showed no significant difference between groups. Sleep quality on the SQS improved in both groups in the first week. The gap leaned toward magnesium bisglycinate but was not statistically significant (p = 0.069). RIS, sleepiness, fatigue, stress, mood and PHQ-4 scores did not differ significantly either. [1]
“No statistically significant time × group interaction was observed in the other questionnaires, as determined by both ITT and PP analyses (Table 2).”
Schuster et al. · Results · full text
Side effects were few in this short trial. 93% of participants reported no adverse events. Table 5 lists 2 self-reported adverse events in the magnesium bisglycinate group and 7 in the placebo group. [1]
“There were no reports of any serious adverse events in the trial, although two participants in the placebo group withdrew due to reported gastrointestinal issues.”
Schuster et al. · Results · full text
What this doesn't tell us
Every outcome came from questionnaires. Sleep was not measured objectively, for example with actigraphy or polysomnography, and fewer than 10% of participants completed the voluntary sleep diary, too few to interpret. [1]
“The validity of the sleep-related outcomes is limited by the exclusive reliance on self-reported data without objective verification.”
Schuster et al. · Discussion · full text
The capsules delivered 1523 mg of glycine along with the magnesium, so this trial can’t separate the two. The authors discuss a possible role for glycine themselves. [1]
“Although magnesium is postulated to be the main contributor to the observed effects, glycine may provide complementary benefits.”
Schuster et al. · Discussion · full text
Participants were adults aged 18 to 65 who described themselves as healthy, and about 80% were women. People with known sleep disorders such as sleep apnea, rotating-shift workers, people taking sleep or mood medications and people with severe chronic diseases, including renal insufficiency, were excluded. The results may not apply to insomnia disorder, older adults or people with kidney disease. [1]
Magnesium status was not measured with blood or urine tests. An exploratory analysis linked lower self-reported intake of magnesium-rich foods with larger ISI improvements in the magnesium bisglycinate group (Spearman’s rho = −0.25, p = 0.036). Diet was rated on a single non-validated question, so this is a hypothesis for future trials, not a finding. [1]
The trial lasted four weeks, and 21 of the 155 randomized participants did not complete it. It was funded by the Institute of Food and One Health, Leibniz University Hannover, as an internal academic project. One author, Adrian Lopresti, is managing director of a contract research organization that receives research funding from nutraceutical companies. [1]
What to take away
Opinion, not a study result: If I were in your spot and sleeping poorly, I would talk to a doctor or pharmacist before adding magnesium, especially with kidney problems or other medications. In this trial the average extra improvement over placebo was small, and the authors say supplementation alone is unlikely to eliminate insomnia in many individuals. If sleep problems persist, talk to a doctor.
Reference
- Nat Sci Sleep 2025[1] Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nature and Science of Sleep. 2025;17:2027–2040.
DOI: 10.2147/NSS.S524348 · Full text
This is a research explainer for general education, not medical advice. If sleep problems persist, talk to a doctor about your options.
